Form 4 for AGIO AGIOS PHARMACEUTICALS, INC.
Accepted 2022-02-23 00:00:00 ET · period of report 2022-02-18 · accession 0001439222-22-000020 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-02-23 | 2022-02-18+ | AGIO | Poddar Richa | Chief Commercial Off | M - OptEx | $0.00 | +2,542 | 5,183 | +96% | $0 |
| D | 2022-02-23 | 2022-02-22 | AGIO | Poddar Richa | Chief Commercial Off | F - Tax | $29.08 | -742 | 4,441 | -14% | -$21.6K |
| DM | 2022-02-23 | 2022-02-18+ | AGIO | Poddar Richa | Chief Commercial Off | M - OptEx | $0.00 | -2,542 | 1,883 | -57% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2022-02-18 | M | A | 1,884 | $0.00 | 4,525 | D | — | — | |
| 2 | Common | Common stock | 2022-02-22 | F | D | 742 | $29.08 | 4,441 | D | — | — | |
| 3 | Common | Common stock | 2022-02-22 | M | A | 658 | $0.00 | 5,183 | D | — | — | |
| 4 | Derivative | Restricted stock units | 2022-02-22 | M | D | 658 | $0.00 | 0 | D | — · — to — | 658 Common stock | (F3) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. (F4) The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. |
| 5 | Derivative | Performance share units | 2022-02-18 | M | D | 1,884 | $0.00 | 1,883 | D | — · — to — | 1,884 Common stock | (F1) Each performance share unit represents a contingent right to receive one share of the issuer's common stock. (F2) The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |